Jaguar Health Cuts Debt to Fuel Rare-Disease Drug Development

San Francisco, Monday, 9 March 2026.
On March 9, 2026, Jaguar Health slashed its debt and royalty obligations by 10%, securing vital financial stability to advance its promising rare-disease intestinal failure drug, crofelemer.